Prevantics Maxi Swabstick is a drug owned by Professional Disposables Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 14, 2021. Details of Prevantics Maxi Swabstick's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| USD468424 | Swabstick |
Jan, 2017
(9 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Prevantics Maxi Swabstick's patents.
Latest Legal Activities on Prevantics Maxi Swabstick's Patents
Given below is the list of recent legal activities going on the following patents of Prevantics Maxi Swabstick.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed | 07 Jan, 2003 | USD468424 |
| Issue Notification Mailed | 19 Dec, 2002 | USD468424 |
| Receipt into Pubs | 12 Nov, 2002 | USD468424 |
| Application Is Considered Ready for Issue | 03 Oct, 2002 | USD468424 |
| Workflow - File Sent to Contractor | 03 Oct, 2002 | USD468424 |
| Issue Fee Payment Verified | 30 Sep, 2002 | USD468424 |
| Issue Fee Payment Received | 30 Sep, 2002 | USD468424 |
| Mail Miscellaneous Communication to Applicant | 26 Aug, 2002 | USD468424 |
| Miscellaneous Communication to Applicant - No Action Count | 23 Aug, 2002 | USD468424 |
| Receipt into Pubs | 15 Aug, 2002 | USD468424 |
FDA has granted several exclusivities to Prevantics Maxi Swabstick. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Prevantics Maxi Swabstick, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Prevantics Maxi Swabstick.
Exclusivity Information
Prevantics Maxi Swabstick holds 1 exclusivities. All of its exclusivities have expired in 2021. Details of Prevantics Maxi Swabstick's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-221) | Feb 14, 2021 |
US patents provide insights into the exclusivity only within the United States, but
Prevantics Maxi Swabstick is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Prevantics Maxi Swabstick's family patents as well as insights into
ongoing legal events
on those patents.
Prevantics Maxi Swabstick's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Prevantics Maxi Swabstick's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Feb 14, 2021 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Prevantics Maxi Swabstick Generics:
There are no approved generic versions for Prevantics Maxi Swabstick as of now.
Alternative Brands for Prevantics Maxi Swabstick
There are several other brand drugs using the same active ingredient (Chlorhexidine Gluconate; Isopropyl Alcohol) as Prevantics Maxi Swabstick. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||||
|---|---|---|---|---|---|
| 3m Health Care |
| ||||
| Becton Dickinson Co |
|
About Prevantics Maxi Swabstick
Prevantics Maxi Swabstick is a drug owned by Professional Disposables Inc. Prevantics Maxi Swabstick uses Chlorhexidine Gluconate; Isopropyl Alcohol as an active ingredient. Prevantics Maxi Swabstick was launched by Prof Dspls in 2005.
Approval Date:
Prevantics Maxi Swabstick was approved by FDA for market use on 03 June, 2005.
Active Ingredient:
Prevantics Maxi Swabstick uses Chlorhexidine Gluconate; Isopropyl Alcohol as the active ingredient. Check out other Drugs and Companies using Chlorhexidine Gluconate; Isopropyl Alcohol ingredient
Dosage:
Prevantics Maxi Swabstick is available in swab form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 3.15%;70% (5.1ML) | SWAB | Over the counter | TOPICAL |